Clinical trials: Cytotoxicity
Non-small Cell Lung Cancer (NSCLC)
A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
This is a Phase II, open-label, multi-centre study to determine the safety of a fixed dose of Durvalumab (MEDI4736) (1500 mg) every 4 weeks [q4w] in participants with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), who…
- Trial name
- NCT03693300
- Testing
- Durvalumab
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Trastuzumab or Herceptin is an antibody directed against Her-2. Her-2 is a growth factor receptor which is present on the tumors of 25% of patients with breast cancer.
- Trial name
- NCT00169104
- Testing
- G-CSF, trastuzumab, vinorelbine
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Malignant Glioma, Glioblastoma Multiforme
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
- Trial name
- BrTK02 (NCT00589875)
- Testing
- CAN-2409, Valacyclovir, Temozolomide
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Candel Therapeutics, Inc.
Leukemia, Lymphocytic
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Background: Chronic lymphocytic leukemia (CLL) is a blood cancer. Recombinant human interleukin 15 (IL-15) is a manmade protein. Obinutuzumab is a protein made to deactivate cancer cells.
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Trial name
- NCT03759184
- Testing
- rhIL-15, Obinutuzumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL)
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
Background: Adult T-cell leukemia (ATL) is a rare blood cancer. Researchers want to see if a combination of two drugs - recombinant human interleukin 15 (rhIL-15) and alemtuzumab - is a better treatment for ATL.
- Conditions
- T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T Cell Lymphoma (CTCL)
- Trial name
- NCT02689453
- Testing
- IL-15 plus, alemtuzumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Background: Adult T-cell leukemia/lymphoma (ATLL) and mycosis fungoides/Sezary syndrome (MF/SS) are cancers that form in the T cells, a type of white blood cell that helps with the body's immune response.
- Conditions
- Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome, Mycosis Fungoides
- Trial name
- NCT04185220
- Testing
- Recombinant human Interleukin-15 (rhIL-15), Mogamulizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Clear-Cell Renal Carcinoma
Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
Background: -Clear-cell renal cell carcinoma (ccRCC) is a kind of kidney cancer. The drug avelumab may help direct the immune response to the tumors and can prolong the immune response.
- Trial name
- NCT04150562
- Testing
- rhIL-15, Avelumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral T-cell Lymphoma NOS, Mycosis Fungoides
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Background: Some T-cell lymphomas and leukemias do not respond to standard treatment. Researchers hope to develop a treatment that works better than current treatments.
- Conditions
- Peripheral T-cell Lymphoma NOS, Mycosis Fungoides, Sezary Syndrome, Anaplastic Large Cell Lymphoma
- Trial name
- NCT03905135
- Testing
- rhIL-15, Avelumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)